92539-28-1

Basic information

• Product Name: 4-Piperidinamine, 1-[(3,4-dichlorophenyl)methyl]-
• CAS NO: 92539-28-1
• Molecular Formula: C12H16Cl2N2
• Molecular Weight: 259.178
• Mol File: 92539-28-1.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 4-Piperidinamine, 1-[(3,4-dichlorophenyl)methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Piperidinamine, 1-[(3,4-dichlorophenyl)methyl]-(92539-28-1)
• EPA Substance Registry System: 4-Piperidinamine, 1-[(3,4-dichlorophenyl)methyl]-(92539-28-1)

Safety Data

• Hazardous Substances Data: 92539-28-1(Hazardous Substances Data)

Upstream product

• 50541-93-0 4-amino-1-benzylpiperidine 
• 73889-19-7 tert-butyl (1-benzylpiperidin-4-yl)carbamate 
• 102-47-6 3,4-Dichlorophenylmethyl chloride 
• 6287-38-3 3,4-dichlorobenzaldehyde 
• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 
• 328083-79-0 4-tert-butoxycarbonylamino-1-(3,4-dichlorobenzyl)piperidine 
• 380423-95-0 1-(3,4-dichloro-benzyl)-piperidine-4-carboxylic acid amide 

Downstream Products

• 479556-00-8 C₂₁H₂₄Cl₂N₂O₃ 
• 384345-92-0 N-(2-{3-[1-(3,4-Dichloro-benzyl)-piperidin-4-ylamino]-2-hydroxy-propoxy}-phenyl)-benzamide 
• 328083-68-7 N-[1-(3,4-dichlorobenzyl)-4-piperidinyl]-N-[3-[3-(2-pyridinyl)-1,2,4-oxadiazo-5-yl]propyl]amine 
• 328083-43-8 1-[3,4-Dichlorobenzyl]-N-[3-(3-pyridinyl)propyl]-4-piperidinamine 

Relevant articles and documents

Design and development of novel thiazole-sulfonamide derivatives as a protective agent against diabetic cataract in Wistar rats via inhibition of aldose reductase

In recent years, ALR2 (aldose reductase) inhibitors have attracted attention for their effective ability to reduce the progression of diabetes-associated cataracts. Therefore, in the present article, we intended to develop novel thiazole-sulfonamide hybrids as a potent inhibitor of ALR2. These molecules significantly inhibited the ALR2 level in the rat lenses homogenate, where the most potent compound 7b showed activity comparable to sorbinil as standard. In Wistar rats, compound 7b improved the insulin level and body weight of the experimental animal together with a reduction in the glucose output. Compound 7b showed a significant reduction in the expression of ALR2 in rat lenses in western blot analysis.

Design and development of a novel chalcone derivative as an anticholinesterase inhibitor for possible treatment of dementia

Background: Cognitive decline (e.g., memory loss), which mainly occurs in the elderly, is termed dementia. In the present study, we intended to explore the cholinesterase inhibitory activity of some novel synthesized chalcones, together with their effect on β-amyloid anti-aggregation. Material/Methods: A novel class of chalcone derivatives have been synthesized and characterized by FT-IR,1H-NMR,13C-NMR, and mass and elemental analysis. These derivatives were later used for the determination of acetylcholinesterase (AChE) inhibitory and β-amyloid anti-aggregation activity. Results: The results of the study showed that among the developed compounds, 8g inhibits AChE more prominently than BuChE, as suggested by a selectivity index (SI) of 2.88. Furthermore, the most potent compound, 8g, showed considerable action in inhibition of β-secretase and Aβ aggregation, but not as prominent as that of curcumin as a standard. Conclusions: In conclusion, our study revealed a novel class of chalcone derivatives as a selective inhibitor of AChE with considerably action against β-secretase and Aβ aggregation. Our results may be useful in developing AD drug therapy and warrant further investigation to generate more advanced analogues.

Novel compounds

The invention provides compounds of general formula (I) wherein m, n, Q, Z1, Z2, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.